Welcome to our dedicated page for Plandai Biotechnology news (Ticker: PLPL), a resource for investors and traders seeking the latest updates and insights on Plandai Biotechnology stock.
Plandai Biotechnology, Inc. (PLPL) specializes in advanced botanical extraction technologies for the global nutraceutical and pharmaceutical markets. This page serves as the definitive source for verified corporate disclosures, including regulatory filings, product development milestones, and strategic business updates.
Investors and industry professionals will find timely updates on the company's Phytofare® extract line development, agricultural operations in South Africa, and material corporate actions. Recent coverage includes the rescission of the Good Salt LLC agreement following shareholder approval, demonstrating our commitment to transparent reporting of significant business developments.
The news archive maintains comprehensive records of financial disclosures, partnership announcements, and operational updates from Plandai's dual focus areas: proprietary extract development and sustainable agricultural production. Key areas of coverage include clinical research progress, intellectual property updates, and production capacity expansions.
Bookmark this page for direct access to primary source materials and official statements regarding Plandai's innovative work in catechin-rich formulations and agricultural asset management. Check regularly for updates on regulatory submissions and global market expansion initiatives.
Plandai Biotechnology, Inc. (OTC PINK:PLPL) has announced a binding memorandum of understanding to acquire Good Salt, LLC, which includes the assets and operations of ByoPlanet International and Clean Republic. ByoPlanet specializes in electrostatic cleaning technology that improves disinfection efficiency and reduces chemical usage. This acquisition aligns with Plandai's new strategic direction, focusing on health technology innovation. Additionally, Plandai is preparing for a potential up listing, having completed audits for its fiscal years ending June 30, 2022, and June 30, 2021. The company plans to change its name to ByoPlanet, Inc. and seek a new trading symbol, pending regulatory approval.
Plandai Biotechnology, Inc. (OTC: PLPL) has terminated its asset acquisition agreement with EV Hotel Corp. without incurring any penalties. This decision was mutually agreed upon by both parties. Additionally, the Company has completed a two-year independent audit of its financial statements, which will inform future disclosures and ongoing merger efforts. Plandai seeks to generate shareholder value by merging with entities offering growth opportunities.
